Atrium Therapeutics Doses First Patient in Phase 1/2 Trial of PRKAG2 Syndrome Therapy

PUBT · 2d ago
Atrium Therapeutics Doses First Patient in Phase 1/2 Trial of PRKAG2 Syndrome Therapy
  • Atrium Therapeutics on Oct. 27, 2026, announced first-patient dosing in its Phase 1/2 Corventis trial for PRKAG2 syndrome.
  • The global trial will evaluate ATR 1072 in approximately 37 participants, with initial proof-of-concept data expected in the second half of 2027.
  • ATR 1072 is an antibody-oligonucleotide conjugate designed to silence mutant PRKAG2 messenger RNA to normalize AMPK overactivity and improve heart function.
  • Corventis is the first interventional clinical trial for PRKAG2 syndrome, a life-threatening genetic cardiomyopathy with no approved therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA81748) on October 27, 2026, and is solely responsible for the information contained therein.